Literature DB >> 3539211

Hormonal probes of central serotonergic activity: do they really exist?

H M van Praag, C Lemus, R Kahn.   

Abstract

The response of a hormone allegedly under 5-hydroxytryptaminergic (5-HT-ergic) control to a compound stimulating or inhibiting serotonergic activity has been used as a measure of the functional state of central serotonergic systems. The relevant literature is reviewed, and based on that, it is concluded that, as yet, no reliable hormonal 5-HT probe exists. The main problems are nonselectivity of the challengers and noncomparability of individual studies because of variations in dose and route of administration. An acceptable hormonal 5-HT probe should at least have passed the following three tests. The influence of the challenger on catecholaminergic (CA) systems must be rendered unlikely in humans to avoid the pitfalls of, say, the 5-HT precursors whose CA-ergic influences have been overlooked. Dose-response relationships must be established to avoid the confusion caused by different investigators using the challenger in different doses. It must be demonstrated that the effect of the challenger is counteracted by its functional opponent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3539211     DOI: 10.1016/0006-3223(87)90134-x

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  11 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

2.  Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder.

Authors:  R S Kahn; G M Asnis; S Wetzler; H M van Praag
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Platelet monoamine oxidase B (MAO-B) activity and its relationship to DL-fenfluramine-induced prolactin response in healthy men.

Authors:  M Eriksson; U Berggren; C Fahlke; J Engel; J Balldin
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

4.  Elevated prolactin responses to L-tryptophan infusion in medication-free depressed patients.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Margaret S Smith; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2003-05-01       Impact factor: 4.530

Review 5.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

6.  Hospital cardiovascular deaths and total distribution of deaths in 180 consecutive months with different cosmic physical activity: a correlative study (1974-1988).

Authors:  E Stoupel; M Shimshoni
Journal:  Int J Biometeorol       Date:  1991-06       Impact factor: 3.787

7.  Effects of ipsapirone in healthy subjects: a dose-response study.

Authors:  R S Kahn; R Trestman; B A Lawlor; S Gabriel; M Davidson; L Siever
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

Review 8.  The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.

Authors:  D C Ohuoha; T M Hyde; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  The metabolic fate of infused L-tryptophan in men: possible clinical implications of the accumulation of circulating tryptophan and tryptophan metabolites.

Authors:  G Heuther; G Hajak; A Reimer; B Poeggeler; M Blömer; A Rodenbeck; E Rüther
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects.

Authors:  R S Kahn; M A Kling; S Wetzler; G M Asnis; H van Praag
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.